Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • New law for labelling...

    New law for labelling Drugs, Fixed Dose Combinations: Govt issues Gazette

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-03-08T15:12:32+05:30  |  Updated On 17 Aug 2021 12:01 PM IST

    Objections and suggestions, if any, may be addressed to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, Room No. 414 A, D Wing, Nirman Bhavan, New Delhi – 110011 or e-mailed at drugsdiv-mohfw@gov.in.


    New Delhi: Through a recent Gazette notification, the Central Government has amended the Drugs and Cosmetics Rules, 1945, wherein labelling norms for various drugs and Fixed Dose Combinations (FDCs) is elaborated. The amendment will come into force from April 1 2019.


    The elaboration will help in establishing clarity in naming various drugs and FDCs. The issued law will ensure naming drugs and FDCs in a comprehensible manner wherein the name, font, size, colour code to be printed on the drug case/covering has been emphasized. This will provide relief to consumers while purchasing the same.


    The Gazette clearly mentioned that the government, in consultation with the Drugs Technical Advisory Board, has published for information of all persons likely to be affected thereby and notice has been given that said draft rules shall be taken into consideration on or after the expiry of a period of 10 days from the date on which copies of the Gazette of India containing these draft rules are made available to the public.


    Objections and suggestions are invited from any person within the period specified above and will be considered by the Central Government.


    Objections and suggestions, if any, may be addressed to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, Room No. 414 A, D Wing, Nirman Bhavan, New Delhi – 110011 or e-mailed at drugsdiv-mohfw@gov.in.


    The issued Rule states, In the Drugs and Cosmetics Rules, 1945, in Schedule A,-


    (i) in Form 45, under 'Conditions for Grant of Approval / Permission",-


    (a) for condition (2), the following condition shall be substituted, namely:-




    "(2) The proper name of the drug or fixed dose combination drug other than fixed dose combinations of vitamin and other fixed dose combinations containing three or more drugs, shall be printed or written in a conspicuous manner which shall be at least two font size larger than the brand name or the trade name, if any, and in other cases the brand name or the trade name, if any, shall be written below or after the proper name on the label of the innermost container of the drug or every other covering in which the
    container is packed.";



    (b) in condition (3), for the words "conspicuous red vertical line on the left side running throughout the body of the label which shall not be less than 1 mm in width and", the following words shall be substituted namely;




    "a caution or warning, as applicable, depending on whether the drug is covered under Schedule G or Schedule H or Schedule H1 or Schedule X, as specified in rule 97, in legible black coloured font size in a completely red rectangular box"



    (ii) in Form 46, under 'Conditions for Grant of Approval / Permission",-




    (a) for condition (2), the following condition shall be substituted, namely:-


    "(2) The proper name of the drug or fixed dose combination drug other than fixed dose combinations of vitamin and other fixed dose combinations containing three or more drugs, shall be printed or written in a conspicuous manner which shall be at least two font size larger than the brand name or the trade name, if any, and in other cases the brand name or the trade name, if any, shall be written below or after the proper name on the label of the innermost container of the drug or every other covering in which the container is packed.";



    (b) in condition (3), for the words "conspicuous red vertical line on the left side running throughout the body of the label which shall not be less than 1 mm in width and", the following words shall be substituted namely;




    "a caution or warning, as applicable, depending on whether the drug is covered under Schedule G or Schedule H or Schedule H1 or Schedule X, as specified in rule 97, in legible black coloured font size in a completely red rectangular box"



    Also Read: Labelling norms for high-risk medicines made Stringent, Check out details

    Drugs and Cosmetics ActDrugs and Cosmetics Rulesdrugsdiv-mohfw@gov.inFDCFDC drugsFDCsfixed dose combinationslabelling normlabelling normslawMinistry of Health and Family Welfareprescription drugSCHEDULE GSchedule HSchedule H1Schedule XvitaminVitamin D

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok